MYD88 mutant lymphoplasmacytic lymphoma/WaldenstrÃ¶m macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.

[waldenstrÃ¶m macroglobulinemia]

In a first series from India , we report 32 cases of lymphoplasmacytic lymphoma /WaldenstrÃ¶m macroglobulinemia (LPL /WM ) over 7 years . Here , we analyzed 32 patients with LPL /WM for MYD 88 L 265 P mutation and correlated mutation staus with hematological and biochemical parameters and also with the International Prognostic Scoring System (ISSWM ) and treatment response . Twenty -seven out of 32 cases of LPL /WM (84 .3 %) harbored the MYD 88 L 265 P mutation . MYD 88 wild-type WM was associated with a lower number of tumor cells (p < 0 .01 ) and older age (p = 0 .02 ) and a lower ISSWM score at presentation (p = 0 .03 ) as compared to mutated LPL /WM . On evaluation of response (n = 23 ), 44 .4 % of patients with MYD 88 mutated LPL /WM had progressive disease , whereas no patient in the MYD 88 unmutated group changed their baseline status . We confirm the high frequency of MYD 88 mutations in LPL /WM . Although the number of MYD 88 wild-type cases was limited , our data indicate that MYD 88 may represent an adverse prognostic marker for LPL /WM .

Diseases
Validation

Diseases presenting "whereas no patient in the myd88 unmutated group changed their baseline status" symptom

waldenstrÃ¶m macroglobulinemia

You can validate or delete this automatically detected symptom